<div id="readability-page-1"><div><p><span></span></p><ul><li>Aprea Therapeutics Inc  is expected to  show a fall in quarterly revenue when it reports  results on November 5 (estimated) for the period ending September 30 2025</li><li></li><li>​LSEG's mean analyst estimate for Aprea Therapeutics Inc is for a loss of 34 cents per share. </li><li>The current average analyst rating on the shares is &#34;strong buy&#34; and the breakdown of recommendations is 2 &#34;strong buy&#34; or &#34;buy,&#34; no &#34;hold&#34; and no &#34;sell&#34; or &#34;strong sell.&#34;  </li><li>The mean earnings estimate of analysts was unchanged in the last three months. ​</li><li>Wall Street's median 12-month price target for Aprea Therapeutics Inc is $10.50, about 86.7% above its last closing price of $1.40</li></ul></div></div>

APRE

<p>Aprea Therapeutics Inc is anticipated to report a loss of 34 cents per share for the quarter ending September 30, 2025, with a decline in revenue expected. Analysts maintain a "strong buy" rating, with no holds or sells. The median 12-month price target is $10.50, representing an 86.7% increase from the last closing price of $1.40. The mean earnings estimate has remained unchanged over the past three months.</p>

Aprea Therapeutics Inc expected to post a loss of 34 cents a share - Earnings Preview